MRK Merck & Company Inc. (new)

80.77
+0.94  (+1%)
Previous Close 79.83
Open 79.77
Price To Book 6.48
Market Cap 210032409905
Shares 2,600,376,500
Volume 7,924,431
Short Ratio 2.53
Av. Daily Volume 13,319,685

NewsSee all news

  1. Merck & Co Inc (MRK) Chairman, President & CEO Kenneth C Frazier Sold $7.7 million of Shares
  2. Merck to Buy Immunotherapy Developer Immune Design for $300M
  3. What's in the Cards for Perrigo (PRGO) This Earnings Season?
  4. Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates
  5. Dow 30 Stock Roundup: WMT Earnings Beat, MRK's Keytruda sBLA Gets Priority Review

SEC filingsSee all SEC filings

  1. SC TO-C - Written communication relating to an issuer or third party
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
  3. SC 13G - Statement of acquisition of beneficial ownership by individuals
  4. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19585168
  5. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19571253

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

FDA Approval announced February 19, 2019.
KEYTRUDA - EORTC1325/KEYNOTE-054
Melanoma
Approval announced June 13, 2018.
Keytruda
Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
FDA approval (label expansion) announced June 5, 2018.
KEYTRUDA + chemo (KEYNOTE-021)
First-Line Nonsquamous Non-small cell lung cancer (NSCLC)
Phase 3 trial did not meet primary endpoint - July 24, 2017. Awarded accelerated approval in 2016.
KEYNOTE-040 KEYTRUDA
Recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)
Tentative approval announced July 20, 2017 - subject to an automatic stay due to a lawsuit from Sanofi claiming patent infringement.
LUSDUNA Nexvue
Diabetes
Phase 3 clinical hold announced July 6, 2017.
KEYTRUDA - KEYNOTE-183
Multiple myeloma
Phase 3 clinical hold announced July 6, 2017.
KEYTRUDA - KEYNOTE-185
Multiple myeloma
Approved Sept. 22, 2017 under accelerated approval in patients undergoing third-line treatment following data from Phase 2 Keynote-59 trial. Phase 3 data released December 14, 2017 in patients undergoing second-line treatment, did not meet the primary endpoint of overall survival, nor did it show a significant improvement in PFS.
Keytruda
Cancer - Third-line Gastric or Gastroesophageal Junction Adenocarcinoma
Phase 1/2 various presentations at ASCO June 5, 2017. Updated data at ESMO Saturday, 9 September 2017 showed ORR 56% in melanoma patients.
Epacadostat with Keytruda - ECHO-202/KEYNOTE-037
NSCLC, RCC, Triple-Negative Breast, Ovarian, Urothelial Carcinoma, Solid Tumors
CRL issued April 7 2017. sNDA for approved drug requested to include data on cardiovascular effects
Januvia (Sitagliptin)
Type 2 Diabetes
Approved March 1, 2017.
Odactra (MK-8237)
House dust mite allergies
FDA Approval announced August 30, 2018. PDUFA date for sNDA September 20, 2019.
PIFELTRO (doravirine)
HIV
Approved May 18, 2017.
KEYTRUDA
First and Second line locally advanced or metastatic urothelial cancer - bladder cancer
FDA label expansion announced January 31, 2019.
(MK-3475-189/KEYNOTE-189)
First Line Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
Approval announced December 20, 2017.
Ertugliflozin
Type 2 diabetes
Phase 3 interim analysis by DMC advised trial to be discontinued due to lack of benefit vs risk.
MK-8931 (019) - Verubecestat
Mild-to-moderate Alzheimer's
Approval announced November 9, 2017.
Letermovir
Cytomegalovirus (CMV) Infection
Phase 3 trial stopped due to lack of efficacy - February 14, 2017.
MK-8931 (017) - Verubecestat
Mild-to-moderate Alzheimer's
Phase 3 trial met its primary endpoint - October 2016. Updated data presented at ASCO 2017. HR 0.70. OS 10.3 months.
Keytruda - KEYNOTE-045
Bladder Cancer
Phase 3 planned.
Epacadostat with Keytruda
Non-small cell lung cancer (NSCLC)
Phase 3 planned.
Epacadostat with Keytruda -
Bladder cancer
Phase 3 planned.
Epacadostat with Keytruda -
Cancer - squamous cell carcinoma of the head and neck
Phase 3 data due released June 27, 2017. Primary endpoint met but noted August 29, 2017 that key secondary endpoint was not met. Announced October 11, 2017 that it will not seek regulatory approval.
Anacetrapib (MK-0859)
Raising HDL-C and reducing LDL-C
Approved May 10, 2017.
Keytruda
First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
Phase 3 data due 2H 2019 or 1H 2020.
MK-7264
Chronic cough
Approval announced March 14, 2017.
KEYTRUDA
Relapsed or Refractory Classical Hodgkin Lymphoma
PDUFA date March 8, 2017 extended to June 9, 2017 due to submission of extra data. Approved May 23, 2017.
KEYTRUDA
Microsatellite Instability-High Cancer
BLA acceptance announced May 23, 2016 by partner Samsung Bioepis. Approval annuonced April 21, 2017.
RENFLEXIS - SB2 (infliximab biosimilar)
Biosimilar candidate of Remicade
Approval announced May 30, 2017.
ISENTRESS
HIV-1
FDA Approval announced December 19, 2018.
Lynparza - SOLO 1
First-line ovarian cancer following platinum-based chemotherapy
Phase 3 data released February 17, 2016 - primary endpoint met. Late breaker at ASCO June 4, 2017 showed HR of 0.58 (42% reduction of risk of disease progression or death). Approval announced January 12, 2018.
Lynparza
Breast cancer
Phase 3 trial did not meet primary endpoint - noted April 6, 2018.
Epacadostat with Keytruda - ECHO-301
Cancer - first-line metastatic melanoma.
Approval announced June 12, 2018.
KEYTRUDA
Cervical cancer
Phase 3 data due 1H 2019.
Lynparza
Pancreatic cancer
PDUFA date under priority review extended to April 11, 2019.
Keytruda - KEYNOTE-042
Non-small cell lung cancer (NSCLC)
Phase 3 data due 2020.
Lynparza - OlympiA
HER2-negative breast cancer
FDA approval announced October 30, 2018.
KEYTRUDA + carboplatin-paclitaxel or nab-paclitaxel KEYNOTE-407
Squamous non-small cell lung cancer (sNSCLC)
Phase 3 data due 2H 2019.
Lynparza
Castration-Resistant Prostate Cancer
Approval announced October 5, 2018.
GARDASIL 9
Human Papilloma virus vaccine
Phase 3 data due 2H 2019.
Lynparza + Avastin- PAOLA-1
First-line ovarian cancer
Phase 3 data due 1H 2019.
Keytruda KN-062
Gastric cancer
Phase 3 data February 19, 2019 did not meet primary endpoints.
Keytruda KN-240
Hepatocellular Carcinoma
Phase 3 data estimated 1H 2019.
Keytruda KN-204
Classical Hodgkin Lymphoma
Phase 3 data estimated 1H 2019.
Keytruda KN-119
Triple negative breast cancer (TNBC)
PDUFA date under priority review June 10, 2019.
Keytruda KN-048
Head and neck squamous cell carcinoma (HNSCC)
Phase 3 data estimated 1H 2019.
Keytruda KN-522
Triple negative breast cancer (TNBC)
FDA approval announced November 9, 2018.
Keytruda - KEYNOTE-224
Hepatocellular carcinoma (HCC)
FDA approval announced August 16, 2018.
LENVIMA (lenvatinib)
Hepatocellular Carcinoma (HCC)
FDA Approval announced December 19, 2018.
Keytruda KN-17
Merkel Cell Carcinoma
PDUFA date under priority review June 3, 2019.
ZERBAXA(ceftolozane and tazobactam)
Hospital-acquired bacterial pneumonia (HABP)
Phase 1 data at ESMO October 2018 noted zero responses in monotherapy arm, 24% with Keytruda.
MK-1454 - STING
Solid tumors
PDUFA date under priority review June 20, 2019.
KEYTRUDA and Inlyta - KEYNOTE-426
Renal cell carcinoma
Phase 3 data due 1H 2020.
Vericiguat
Heart Failure
Phase 3 data due 2H 2019.
Keytruda KN-355
Triple negative breast cancer (TNBC)
Phase 3 trial did not meet primary endpoint of OS in intend-to-treat population. Endpoint met in squamous cell carcinoma or adenocarcinoma groups.
Keytruda KN-181
Esophageal Cancer
Phase 3 data due 2H 2019.
Keytruda KN-177
Colorectal cancer (CRC)
Phase 3 data due 1H 2019.
Keytruda KN-361
Bladder cancer
Phase 3 data due 1H 2019.
Keytruda KN-057
NMIBC Bladder cancer
Phase 3 data due 1H 2019.
Keytruda KN-604
Small cell lung cancer (SCLC)
Phase 3 data due 1H 2020.
LENVIMA (lenvatinib) + Keytruda - KN-581
Renal cell carcinoma (RCC) - cancer
Phase 3 data due 1H 2020.
LENVIMA (lenvatinib) + Keytruda - KN-581
Renal cell carcinoma (RCC) - cancer
Rolling BLA filing has commenced - noted November 13, 2018.
V920
Ebola
PDUFA date for sNDA September 20, 2019.
DELSTRIGO (doravirine/lamivudine/tenofovir disoproxil fumarate)
HIV
Phase 3 data due 2020.
Keytruda KN-122
Nasopharyngeal Carcinoma
PDUFA date under priority review July 16, 2019.
Imipenem/ cilastatin
Complicated urinary tract infections (cUTI) and Complicated intra-abdominal infections (cIAI)
PDUFA date under priority review June 17, 2019.
Keytruda - KN-158
Small cell lung cancer (SCLC)

Latest News

  1. Merck & Co Inc (MRK) Chairman, President & CEO Kenneth C Frazier Sold $7.7 million of Shares
  2. Merck to Buy Immunotherapy Developer Immune Design for $300M
  3. What's in the Cards for Perrigo (PRGO) This Earnings Season?
  4. Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates
  5. Dow 30 Stock Roundup: WMT Earnings Beat, MRK's Keytruda sBLA Gets Priority Review
  6. ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Immune Design Corp.
  7. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Immune Design Corp. to Merck & Co., Inc. for $5.85 Per Share is Fair to Shareholders
  8. Merck To Buy Immune Design For $300M
  9. Merck Gets Priority Review for Keytruda in Third-Line SCLC
  10. Immune Design (IMDZ) Alert: Johnson Fistel Investigates Proposed Sale of Immune Design Corp.; Are Immune Design Shareholders Getting a Fair Deal?
  11. Merck to buy immunotherapy developer Immune Design for $300 mln
  12. Merck to Acquire Immune Design
  13. Edited Transcript of MRK earnings conference call or presentation 1-Feb-19 1:00pm GMT
  14. Why Merck (MRK) is a Top Dividend Stock for Your Portfolio
  15. Merck's Keytruda Fails to Meet Endpoint in Liver Cancer Study
  16. Intercept Reports Positive Top-Line Data for NASH, Shares Up
  17. Merck expands Mass. reach with Torque cancer collaboration
  18. Merck Shares Drop After Keytruda Treatment Fails Late-Stage Liver Cancer Trial
  19. The Daily Biotech Pulse: Teva Settles With FTC, Setback For Merck In Liver Cancer Trial, Sienna Biopharma Offering
  20. New Research: Key Drivers of Growth for DISH Network, Avon Products, Merck & Co., Laredo Petroleum, Health Insurance Innovations, and Bruker — Factors of Influence, Major Initiatives and Sustained Production

SEC Filings

  1. SC TO-C - Written communication relating to an issuer or third party
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
  3. SC 13G - Statement of acquisition of beneficial ownership by individuals
  4. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19585168
  5. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19571253
  6. 8-K/A [Amend] - Current report 19560228
  7. 8-K - Current report 19557684
  8. 8-K - Current report 19551259
  9. 8-K - Current report 181227104
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 181163124